Ventripoint Announces Closing of $308,030 Non-Brokered Units Private Placement

About this update from Ventripoint Diagnostics Ltd.

(via TheNewswire) Toronto, Ontario, May 22, 2026 – TheNewswire - Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Corporation”) (TSXV:VPT) is pleased to announce the closing of a non-brokered private placement of 2,800,273 units (each, a “Unit”) at a price of $0.11 per Unit for aggregate gross proceeds of $308,030 (the “Offering”), subject to TSXV Venture Exchange (the “Exchange”) acceptance. Each Unit will be comprised of one (1) common share (“Common Shares”) of the Corporation, and one (1) common share purchase warrant (“Warrants”).   Each whole Warrant will entitle the holder thereof to purchase one (1) Common Share at a price of $0.14 for a period of 24 months from the closing of the Offering.   The Corporation will use the proceeds of the Offering to fund sales and marketing initiatives, operational costs  and general working capital. No finders’ fees were paid related to the Offering.   The Offering is a related party transaction within the meaning of TSXV Policy 5.9 and Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions (“MI-61-101”) as an insider of the Corporation subscribed for 136,364 Units on the same terms as arm’s length subscribers. The Corporation is relying on exemptions from the valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(a) and (b) and 5.7(a) and (b) of MI 61-101, as the Corporation is not listed on a specified market and the fair market value of the participation in the transactions by insiders does not exceed 25% of the market capitalization of the Corporation, as determined in accordance with MI 61-101 and the fair market value of the transactions is not more than $2,500,000. The Corporation did not file a material change report in respect of the related party transaction at least 21 days before the closing of the Offering, which the Corporation deems reasonable in the circumstances in order to complete the transaction.   All securities issued and issuable pursuant to the Offering will be subject to a hold period of four months plus one day from the date of closing of the Offering. The Offering is subject to approval by the Exchange.   The securities offered will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent a registration st...

View stock analysis, news, and events for Ventripoint Diagnostics Ltd.